Anti-Oxidant Drugs: Novelties and Clinical Implications in Cerebellar Ataxias
Author:
Barca Emanuele1, Emmanuele Valentina1, DiMauro Salvatore1, Toscano Antonio2, Quinzii Catarina M.1
Affiliation:
1. Department of Neurology, Columbia University Medical Center, New York, NY, 10032, United States 2. Department of Clinical and Experimental Medicine, University of Messina, Messina, 98125, Italy
Abstract
Background:Hereditary cerebellar ataxias are a group of disorders characterized by heterogeneous clinical manifestations, progressive clinical course, and diverse genetic causes. No disease modifying treatments are yet available for many of these disorders. Oxidative stress has been recurrently identified in different progressive cerebellar diseases, and it represents a widely investigated target for treatment. </P><P> Objective: To review the main aspects and new perspectives of antioxidant therapy in cerebellar ataxias ranging from bench to bedside. </P><P> Method: This article is a summary of the state-of-the-art on the use of antioxidant molecules in cerebellar ataxia treatments. It also briefly summarizes aspects of oxidative stress production and general characteristics of antioxidant compounds. </P><P> Results: Antioxidants represent a vast category of compounds; old drugs have been extensively studied and modified in order to achieve better biological effects. Despite the vast body of literature present on the use of antioxidants in cerebellar ataxias, for the majority of these disorders conclusive results on the efficacy are still missing.Conclusion:Antioxidant therapy in cerebellar ataxias is a promising field of investigations. To achieve the success in identifying the correct treatment more work needs to be done. In particular, a combined effort is needed by basic scientists in developing more efficient molecules, and by clinical researchers together with patients communities, to run clinical trials in order to identify conclusive treatments strategies.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical),Neurology,Pharmacology,General Medicine
Reference130 articles.
1. Bodranghien F, Bastian A, Casali C, Hallett M, Louis ED, Manto M, Mariën P, Nowak DA, Schmahmann JD, Serrao M, Steiner KM, Strupp M, Tilikete C, Timmann D, van Dun K. Cerebellum, Consensus paper: Revisiting the symptoms and signs of cerebellar syndrome.,, 2016, 15,, 369-391,[http://dx.doi. org/10.1007/s12311-015-0687-]. [PMID: 261050]. 2. Manto M, Haines D. Cerebellum, Cerebellar research: two centuries of discoveries.,, 2012, 11,, 446-448,[http://dx.doi.org/10. 1007/s12311-011-0336-]. [PMID: 2211350]. 3. Manto M. Cerebellum, The cerebellum, cerebellar disorders, and cerebellar research--two centuries of discoveries.,, 2008, 7,, 505-516,[http://dx.doi.org/10.1007/s12311-008-0063-]. [PMID: 188550]. 4. Ilg W, Bastian AJ, Boesch S, Burciu RG, Celnik P, Claaßen J, Feil K, Kalla R, Miyai I, Nachbauer W, Schöls L, Strupp M, Synofzik M, Teufel J, Timmann D. Cerebellum, Consensus paper: Management of degenerative cerebellar disorders.,, 2014, 13,, 248-268,[http://dx.doi.org/10.1007/s12311-013-0531-]. [PMID: 242226]. 5. Giannoccaro MP, La Morgia C, Rizzo G, Carelli V. Mov Disord, Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson’s disease.,, 2017, 32,, 346-363,[http://dx.doi. org/10.1002/mds.269]. [PMID: 282516].
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|